TMCnet News
Research and Markets: 2014 Report on the US Hepatitis C Virus Market - Forecasts to 2022DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/vw7pvx/pharmapoint) has announced the addition of the "2014 Report on the US Hepatitis C Virus Market - Forecasts to 2022" report to their offering. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche's Pegasys and Merck's PegIntron) and ribavirin (e.g., Roche's Copegus and Merck's Rebetol) are used to treat HCV infection.
Vertex's Incivek is the current market leader. It was among the first DAA HCV therapies launched in the US. Incivek's improved efficacy over the previous standard of care (i.e., peginterferon and ribavirin combination therapy) in the treatment of the most prevalent HCV genotype in the US, HCV GT1, enabled the drug to quickly capture the market. Scope
Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Market Outlook 9 Appendix For more information visit http://www.researchandmarkets.com/research/vw7pvx/pharmapoint
|